Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...
News Medical on MSN3d
Globally prostate and testicular cancer rates climb, but mortality is fallingNew research maps the global burden of male cancers from 1990 to 2040, showing how aging, lifestyle, and healthcare access ...
Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk ...
Professor Adrian Crellin, 70, noticed blood in his urine and promptly sought medical attention from his GP, leading to a ...
Savita Dandapani, MD, PhD, discusses the rationale behind a study evaluating the combination of radium-223, hormone therapy, ...
Further tests, such as CT scans and bone scans, may be performed to determine whether prostate ... the extent of metastasis, appearance under the microscope and response of the cancer to initial ...
Medpage Today on MSN1d
What's the Better Option for High-Risk Prostate Cancer -- Radiation or Surgery?SAN FRANCISCO -- Patients with high-risk prostate cancer had a significantly lower incidence of distant metastasis when ...
From 1,085 citations identified, 48 studies with 15,368 men with mCRPC met inclusion criteria. Most studies were retrospective cohorts (n = 39) from Europe (n = 22) and North America (n = 18), with ...
Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback